Imunon annual net profit margin
2017
2018
2019
2020
2021
2022
Imunon Net Profit Margin Growth & History (IMNN)
Imunon's net profit margin was −7,179.65% for fiscal 2022.
View full Imunon company overviewImunon annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2022 | 2022-12-31 | −7,179.65% | −3025.80 pp |
| 2021 | 2021-12-31 | −4,153.85% | +142.86 pp |
| 2020 | 2020-12-31 | −4,296.71% | −926.41 pp |
| 2019 | 2019-12-31 | −3,370.31% | −993.63 pp |
| 2018 | 2018-12-31 | −2,376.67% | +1703.76 pp |
| 2017 | 2017-12-31 | −4,080.44% | — |
Imunon quarterly net profit margin
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q3.15
Q4.15
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q4 2022 | 2022-12-31 | −10,586.14% | −7209.10 pp |
| Q3 2022 | 2022-09-30 | −4,918.63% | −590.20 pp |
| Q2 2022 | 2022-06-30 | −4,834.35% | −475.63 pp |
| Q1 2022 | 2022-03-31 | −8,379.47% | −3828.26 pp |
| Q4 2021 | 2021-12-31 | −3,377.04% | −967.32 pp |
| Q3 2021 | 2021-09-30 | −4,328.44% | +2128.84 pp |
| Q2 2021 | 2021-06-30 | −4,358.72% | −84.37 pp |
| Q1 2021 | 2021-03-31 | −4,551.20% | −505.70 pp |
| Q4 2020 | 2020-12-31 | −2,409.72% | +72.49 pp |
| Q3 2020 | 2020-09-30 | −6,457.28% | −2075.83 pp |
| Q2 2020 | 2020-06-30 | −4,274.35% | +449.26 pp |
| Q1 2020 | 2020-03-31 | −4,045.50% | −2151.54 pp |
| Q4 2019 | 2019-12-31 | −2,482.21% | −6866.67 pp |
| Q3 2019 | 2019-09-30 | −4,381.45% | −656.34 pp |
| Q2 2019 | 2019-06-30 | −4,723.61% | +1860.83 pp |
| Q1 2019 | 2019-03-31 | −1,893.96% | +1687.63 pp |
| Q4 2018 | 2018-12-31 | 4,384.46% | +7503.97 pp |
| Q3 2018 | 2018-09-30 | −3,725.11% | +811.95 pp |
| Q2 2018 | 2018-06-30 | −6,584.44% | −2047.38 pp |
| Q1 2018 | 2018-03-31 | −3,581.60% | +546.51 pp |
| Q4 2017 | 2017-12-31 | −3,119.51% | — |
| Q3 2017 | 2017-09-30 | −4,537.06% | — |
| Q2 2017 | 2017-06-30 | −4,537.06% | — |
| Q1 2017 | 2017-03-31 | −4,128.11% | — |
| Q4 2015 | 2015-12-31 | −4,411.20% | +752.80 pp |
| Q3 2015 | 2015-09-30 | −3,413.93% | +2139.67 pp |
| Q1 2015 | 2015-03-31 | −5,604.05% | −1265.65 pp |
| Q4 2014 | 2014-12-31 | −5,164.00% | — |
| Q3 2014 | 2014-09-30 | −5,553.60% | — |
| Q2 2014 | 2014-06-30 | −5,338.40% | — |
| Q1 2014 | 2014-03-31 | −4,338.40% | — |
Imunon net profit margin trends
Over the last five fiscal years, Imunon's net profit margin decreased from −4,080.44% to −7,179.65%, a change of −3099.21 percentage points. The latest reported quarter, Q4 2022, shows −10,586.14%.
About the metric
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
Calculation and source
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Imunon source filings ↗Community posts
IMUNON signs an NCI agreement to expand development of IMNN-001
IMUNON ($IMNN) entered a Cooperative Research and Development Agreement with the US National Cancer Institute for IMNN-001, its DNA-based IL-12 immunotherapy. NCI’s Cancer Therapy Evaluation Program will assume regulatory sponsorship and su ...